8-KMaterial AgreementsExhibits & Filings

REGENERON PHARMACEUTICALS, INC. 8-K Report, Material Agreement (Apr 3, 2007)

Filed April 3, 2007For Securities:REGN

Summary

Regeneron Pharmaceuticals, Inc. (REGN) has entered into a significant non-exclusive license agreement with Astellas Pharma Inc. This deal grants Astellas rights to utilize Regeneron's proprietary VelocImmune® technology for the discovery of human monoclonal antibodies. The agreement provides Regeneron with immediate financial benefits and potential future revenue streams, positioning the company's innovative technology as a valuable asset in the pharmaceutical industry.

Key Highlights

  • 1Regeneron entered into a non-exclusive license agreement with Astellas Pharma Inc. on March 30, 2007.
  • 2The agreement grants Astellas rights to use Regeneron's VelocImmune® technology for discovering human monoclonal antibodies.
  • 3Regeneron received a $20 million upfront payment from Astellas.
  • 4Astellas may make up to five additional annual payments of $20 million each, subject to certain conditions including termination rights.
  • 5Regeneron is eligible for mid-single-digit royalties on future sales of antibody products developed by Astellas using the VelocImmune® technology.
  • 6This agreement highlights the commercial value and potential of Regeneron's VelocImmune® platform.

Frequently Asked Questions

VelocImmune® is a proprietary technology developed by Regeneron for the discovery of human monoclonal antibodies. It is a key platform for developing therapeutic antibodies.

Regeneron received a $20 million upfront payment. Additionally, Astellas has the option to make up to five further annual payments of $20 million each. Regeneron is also entitled to receive mid-single-digit royalties on future sales of products discovered using the technology.

Yes, Astellas can terminate the agreement after making the first three additional payments or if the technology does not meet minimum performance criteria, impacting the realization of the full potential $100 million in additional payments.

A non-exclusive license means Regeneron can license its VelocImmune® technology to other companies as well, allowing for broader application and potential revenue generation from multiple partners.